KAN Stock Overview
Develops drugs for inflammatory diseases and cancer in Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Kancera AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.77 |
| 52 Week High | SEK 6.77 |
| 52 Week Low | SEK 1.33 |
| Beta | 1.64 |
| 11 Month Change | 9.64% |
| 3 Month Change | 16.56% |
| 1 Year Change | -63.54% |
| 33 Year Change | -83.10% |
| 5 Year Change | -80.48% |
| Change since IPO | -97.39% |
Recent News & Updates
Recent updates
We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully
Dec 06
Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?
Jul 19Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth
Mar 08We Think Kancera (STO:KAN) Can Afford To Drive Business Growth
Jun 29We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely
Mar 08Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation
Aug 02We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate
Apr 06Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation
Dec 21Shareholder Returns
| KAN | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 3.0% | -6.1% | -0.6% |
| 1Y | -63.5% | 21.0% | 17.0% |
Return vs Industry: KAN underperformed the Swedish Biotechs industry which returned 21% over the past year.
Return vs Market: KAN underperformed the Swedish Market which returned 17% over the past year.
Price Volatility
| KAN volatility | |
|---|---|
| KAN Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: KAN has not had significant price volatility in the past 3 months.
Volatility Over Time: KAN's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5 | Peter Selin | www.kancera.com |
Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy.
Kancera AB (publ) Fundamentals Summary
| KAN fundamental statistics | |
|---|---|
| Market cap | SEK 214.98m |
| Earnings (TTM) | -SEK 60.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.6x
P/E RatioIs KAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KAN income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 60.35m |
| Earnings | -SEK 60.35m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KAN perform over the long term?
See historical performance and comparison